

Supplementary Table SI. Clinical characteristics and correlation with nausea and vomiting

Characteristic	N	Nausea and vomiting		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	41 (25.5)	120 (74.5)	2.1656	0.1411			
Male	39	5 (12.8)	34 (87.2)					
Age at AR diagnosis:								
≤ 45	102	24 (23.5)	78 (76.5)	0.0002	0.9893			
> 45	98	22 (22.4)	76 (77.6)					
Duration of methotrexate treatment:								
≤ 46	102	30 (29.4)	72 (70.6)	4.1215	0.0423	> 46	2.13	1.03–4.54
> 46	98	16 (16.3)	82 (83.7)					
Smoking status:								
Current-smokers	45	11 (24.4)	34 (75.6)	1.5592	0.4586			
Former-smokers	12	1 (8.3)	11 (91.7)					
Non-smokers	143	34 (23.8)	109 (76.2)					
Baseline FR status:								
Positive	136	35 (25.7)	101 (74.3)	1.2259	0.2682			
Negative	63	11 (17.5)	52 (82.5)					
Baseline DAS28 status:								
≤ 5.42	98	18 (18.4)	80 (81.6)	1.9514	0.1624			
> 5.42	101	28 (27.7)	73 (72.3)					

Supplementary Table SII. Clinical characteristics and correlation with anaemia

Characteristic	N	Anaemia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	10 (6.2)	151 (93.8)		1*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	6 (5.9)	96 (94.1)	< 0.01	1			
> 45	98	6 (6.1)	92 (93.9)					
Duration of methotrexate treatment:								
≤ 46	102	4 (3.9)	98 (96.1)	0.93101	0.3346			
> 46	98	8 (8.2)	90 (91.8)					
Smoking status:								
Current-smokers	45	2 (4.4)	43 (95.6)		0.8762*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	10 (7.0)	133 (93.0)					
Baseline FR status:								
Positive	136	10 (7.4)	126 (92.6)		0.3457*			
Negative	63	2 (3.2)	61 (96.8)					
Baseline DAS28 status:								
≤ 5.42	98	6 (6.1)	92 (93.9)	< 0.01	1			
> 5.42	101	6 (5.9)	95 (94.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SIII. Clinical characteristics and correlation with neutropaenia

Characteristic	N	Neutropaenia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	12 (7.5)	149 (92.5)		1*			
Male	39	3 (7.7)	36 (92.3)					
Age at AR diagnosis:								
≤ 45	102	8 (7.8)	94 (92.2)	< 0.01	1*			
> 45	98	7 (7.1)	91 (92.9)					
Duration of methotrexate treatment:								
≤ 46	102	5 (4.9)	97 (95.1)	1.3331	0.2482			
> 46	98	10 (10.2)	88 (89.8)					
Smoking status:								
Current-smokers	45	4 (8.9)	41 (91.1)		0.7194*			
Former-smokers	12	1 (8.3)	11 (91.7)					
Non-smokers	143	10 (7.0)	133 (93.0)					
Baseline FR status:								
Positive	136	12 (8.8)	124 (91.2)	0.5197	0.4710			
Negative	63	3 (4.8)	60 (95.2)					
Baseline DAS28 status:								
≤ 5.42	98	6 (6.1)	92 (93.9)	0.2269	0.6338			
> 5.42	101	9 (8.9)	92 (91.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SIV. Clinical characteristics and correlation with macrocytosis

Characteristic	N	Macrocytosis		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	3 (1.9)	158 (98.1)		0.2514*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	3 (2.9)	99 (97.1)		1*			
> 45	98	2 (2.0)	96 (98.0)					
Duration of methotrexate treatment:								
≤ 46	102	2 (2.0)	100 (98.0)		0.6782*			
> 46	98	3 (3.1)	95 (96.9)					
Smoking status:								
Current-smokers	45	1 (2.2)	44 (97.8)		0.3342*			
Former-smokers	12	1 (8.3)	11 (91.7)					
Non-smokers	143	3 (2.1)	140 (97.9)					
Baseline FR status:								
Positive	136	4 (2.9)	132 (97.1)		1*			
Negative	63	1 (1.6)	62 (98.4)					
Baseline DAS28 status:								
≤ 5.42	98	3 (3.1)	95 (96.9)		0.6796*			
> 5.42	101	2 (2.0)	99 (98.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SV. Clinical characteristics and correlation with thrombocytopenia

Characteristic	N	Thrombocytopenia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	1 (0.6)	160 (99.4)		0.0978*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	2 (2.0)	100 (98.0)		1*			
> 45	98	1 (1.0)	97 (99.0)					
Duration of methotrexate treatment:								
≤ 46	102	1 (1.0)	101 (99.0)		0.6157*			
> 46	98	2 (2.0)	96 (98.0)					
Smoking status:								
Current-smokers	45	1 (2.2)	44 (97.8)		0.0883*			
Former-smokers	12	1 (8.3)	11 (91.7)					
Non-smokers	143	1 (0.7)	142 (99.3)					
Baseline FR status:								
Positive	136	2 (1.5)	134 (98.5)		1*			
Negative	63	1 (1.6)	62 (98.4)					
Baseline DAS28 status:								
≤ 5.42	98	3 (3.1)	95 (96.9)		0.1176*			
> 5.42	101	0 (0.0)	101 (100.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SVI. Clinical characteristics and correlation with anosmia

Characteristic	N	Anosmia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	1 (0.6)	160 (99.4)		0.3528*			
Male	39	1 (2.6)	38 (97.4)					
Age at AR diagnosis:								
≤ 45	102	2 (2.0)	100 (98.0)		0.4977*			
> 45	98	0 (0.0)	98 (100.0)					
Duration of methotrexate treatment:								
≤ 46	102	2 (2.0)	100 (98.0)		0.4977*			
> 46	98	0 (0.0)	98 (100.0)					
Smoking status:								
Current-smokers	45	1 (2.2)	44 (97.8)		0.4898*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	43	1 (0.7)	42 (99.3)					
Baseline FR status:								
Positive	136	2 (1.5)	134 (98.5)		1*			
Negative	63	0 (0.0)	63 (100.0)					
Baseline DAS28 status:								
≤ 5.42	98	1 (1.0)	97 (99.0)		1*			
> 5.42	101	1 (1.0)	100 (99.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SVII. Clinical characteristics and correlation with diarrhoea

Characteristic	N	Diarrhoea		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	27 (16.8)	134 (83.2)	0.3644	0.5461			
Male	39	5 (12.8)	34 (87.2)					
Age at AR diagnosis:								
≤ 45	98	17 (17.3)	81 (82.7)	0.2594	0.6105			
> 45	102	15 (14.7)	87 (85.3)					
Duration of methotrexate treatment:								
≤ 46	102	20 (19.6)	82 (80.4)	2.0160	0.1556			
> 46	98	12 (12.2)	86 (87.8)					
Smoking status:								
Current-smokers	45	8 (17.8)	37 (82.2)		0.3430*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	24 (16.8)	119 (83.2)					
Baseline FR status:								
Positive	136	25 (18.4)	111 (81.6)	1.1911	0.2751			
Negative	63	7 (11.1)	56 (88.9)					
Baseline DAS28 status:								
≤ 5.42	98	14 (14.3)	84 (85.7)	0.2361	0.6271			
> 5.42	101	18 (17.8)	83 (82.2)					

*p-value for Fisher's Exact Test

Supplementary Table SVIII. Clinical characteristics and correlation with mucositis

Characteristic	N	Mucositis		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	19 (11.8)	142 (88.2)		0.5784*			
Male	39	3 (7.7)	36 (92.3)					
Age at AR diagnosis:								
≤ 45	102	12 (11.8)	90 (88.2)	0.0160	0.8993			
> 45	98	10 (10.2)	88 (89.8)					
Duration of methotrexate treatment:								
≤ 46	102	14 (13.7)	88 (86.3)	1.0624	0.3027			
> 46	98	8 (8.2)	90 (91.8)					
Smoking status:								
Current-smokers	45	3 (6.7)	42 (93.3)		0.4031*			
Former-smokers	12	2 (16.7)	10 (83.3)					
Non-smokers	143	17 (11.9)	126 (88.1)					
Baseline FR status:								
Positive	136	12 (8.8)	124 (91.2)	1.5181	0.2179			
Negative	63	10 (15.9)	53 (84.1)					
Baseline DAS28 status:								
≤ 5.42	98	10 (10.2)	88 (89.8)	0.0228	0.8799			
> 5.42	101	12 (11.9)	89 (88.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SIX. Clinical characteristics and correlation with liver failure

Characteristic	N	Liver failure		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	155	73 (47.1)	82 (52.9)	0.0453	0.8314			
Male	39	17 (43.6)	22 (56.4)					
Age at AR diagnosis:								
≤ 45	98	49 (50.0)	49 (50.0)	0.3820	0.7643			
> 45	96	41 (42.7)	55 (57.3)					
Duration of methotrexate treatment:								
≤ 46	99	42 (42.4)	57 (57.6)	0.9746	0.3235			
> 46	95	48 (50.5)	47 (49.5)					
Smoking status:								
Current-smokers	42	18 (42.9)	24 (57.1)	0.3056	0.8583			
Former-smokers	12	6 (50.0)	6 (50.0)					
Non-smokers	140	66 (47.1)	74 (52.9)					
Baseline FR status:								
Positive	133	60 (45.1)	73 (54.9)	0.2248	0.6354			
Negative	60	30 (50.0)	30 (50.0)					
Baseline DAS28 status:								
≤ 5.42	95	46 (48.4)	49 (51.6)	0.1199	0.7292			
> 5.42	98	44 (44.9)	54 (55.1)					

Supplementary Table SX. Clinical characteristics and correlation with dizziness

Characteristic	N	Dizziness		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	17 (10.6)	144 (89.4)		0.2077*			
Male	39	1 (2.6)	38 (97.4)					
Age at AR diagnosis:								
≤ 45	102	11 (10.8)	91 (98.2)	0.4257	0.5141			
> 45	98	7 (7.1)	91 (92.9)					
Duration of methotrexate treatment:								
≤ 46	102	11 (10.8)	91 (98.2)	0.4257	0.5141			
> 46	98	7 (7.1)	91 (92.9)					
Smoking status:								
Current-smokers	45	4 (8.9)	41 (91.1)		0.7519*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	14 (9.8)	129 (90.2)					
Baseline FR status:								
Positive	136	13 (9.6)	123 (90.4)	0.0111	0.9160			
Negative	63	5 (7.9)	58 (92.1)					
Baseline DAS28 status:								
≤ 5.42	98	6 (6.1)	92 (93.9)	1.3661	0.2425			
> 5.42	101	12 (11.9)	89 (88.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SXI. Clinical characteristics and correlation with headache

Characteristic	N	Headache		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	18 (11.2)	143 (88.8)		0.3762*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	12 (11.8)	90 (88.2)	0.3757	0.5399			
> 45	98	8 (8.2)	90 (91.8)					
Duration of methotrexate treatment:								
≤ 46	102	13 (12.7)	89 (87.3)	1.1760	0.2782			
> 46	98	7 (7.1)	91 (92.9)					
Smoking status:								
Current-smokers	45	4 (8.9)	41 (91.1)		1*			
Former-smokers	12	1 (8.3)	11 (91.7)					
Non-smokers	143	15 (10.5)	128 (89.5)					
Baseline FR status:								
Positive	136	16 (11.8)	120 (88.2)	0.8619	0.3532			
Negative	63	4 (6.3)	59 (93.7)					
Baseline DAS28 status:								
≤ 5.42	98	8 (8.2)	90 (91.8)	0.4049	0.5246			
> 5.42	101	12 (11.9)	89 (88.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SXII. Clinical characteristics and correlation with anxiety

Characteristic	N	Anxiety		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	1 (0.6)	160 (99.4)		1*			
Male	39	0 (0.0)	39 (100.0)					
Age at AR diagnosis:								
≤ 45	102	0 (0.0)	102 (100.0)		0.4900*			
> 45	98	1 (1.0)	97 (99.0)					
Duration of methotrexate treatment:								
≤ 46	102	0 (0.0)	102 (100.0)		0.4900*			
> 46	98	1 (1.0)	97 (99.0)					
Smoking status:								
Current-smokers	45	0 (0.0)	45 (100.0)		1*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	1 (0.7)	142 (99.3)					
Baseline FR status:								
Positive	136	1 (0.7)	135 (99.7)		1*			
Negative	63	0 (0.0)	63 (100.0)					
Baseline DAS28 status:								
≤ 5.42	98	0 (0.0)	98 (100.0)		1*			
> 5.42	101	1 (1.0)	100 (99.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SXIII. Clinical characteristics and correlation with metrorrhagia

Characteristic	N	Metrorrhagia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	3 (1.9)	158 (98.1)		1*			
Male	39	0 (0.0)	39 (100.0)					
Age at AR diagnosis:								
≤ 45	102	3 (2.9)	99 (97.1)		0.2465*			
> 45	98	0 (0.0)	98 (100.0)					
Duration of methotrexate treatment:								
≤ 46	102	2 (2.0)	100 (98.0)		1*			
> 46	98	1 (1.0)	97 (99.0)					
Smoking status:								
Current-smokers	45	1 (2.2)	44 (97.8)		0.6367*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	1 (1.4)	141 (98.6)					
Baseline FR status:								
Positive	136	3 (2.2)	133 (97.8)		0.5530*			
Negative	63	0 (0.0)	63 (100.0)					
Baseline DAS28 status:								
≤ 5.42	98	0 (0.0)	98 (100.0)		0.2464*			
> 5.42	101	3 (3.0)	98 (97.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SXIV. Clinical characteristics and correlation with pulmonary toxicity

Characteristic	N	Pulmonary toxicity		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	6 (3.7)	155 (96.3)		1*			
Male	39	1 (2.6)	38 (97.4)					
Age at AR diagnosis:								
≤ 45	102	4 (3.9)	98 (96.1)		1*			
> 45	98	3 (3.1)	95 (96.9)					
Duration of methotrexate treatment:								
≤ 46	102	5 (4.9)	97 (95.1)		0.4454*			
> 46	98	2 (2.0)	96 (98.0)					
Smoking status:								
Current-smokers	45	1 (2.2)	44 (97.8)		1*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	6 (4.2)	137 (95.8)					
Baseline FR status:								
Positive	136	6 (4.4)	130 (95.6)		0.4354*			
Negative	63	1 (1.6)	62 (98.4)					
Baseline DAS28 status:								
≤ 5.42	98	3 (3.1)	95 (96.9)		1*			
> 5.42	101	4 (4.0)	97 (96.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SXV. Clinical characteristics and correlation with alopecia

Characteristic	N	Alopecia		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	23 (14.3)	138 (85.7)		0.1763*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	11 (10.8)	91 (89.2)	0.5602	0.4542			
> 45	98	14 (14.3)	84 (85.7)					
Duration of methotrexate treatment:								
≤ 46	102	10 (9.8)	92 (90.2)	1.3834	0.2395			
> 46	98	15 (15.3)	83 (84.7)					
Smoking status:								
Current-smokers	45	4 (8.9)	41 (91.1)	0.8079	0.6677			
Former-smokers	12	2 (16.7)	10 (83.3)					
Non-smokers	43	19 (13.3)	124 (86.7)					
Baseline FR status:								
Positive	136	16 (11.8)	120 (88.2)	0.2491	0.6177			
Negative	63	9 (14.3)	54 (85.7)					
Baseline DAS28 status:								
≤ 5.42	98	10 (10.2)	88 (89.8)	0.9779	0.3227			
> 5.42	101	15 (14.9)	86 (85.1)					

*P-value for Fisher's Exact Test.

Supplementary Table SXVI. Clinical characteristics and correlation with rash acneiform

Characteristic	N	Rash acneiform		χ^2	P-value	Cat Ref.	OR	95% CI
		Yes n (%)	No n (%)					
Gender:								
Female	161	7 (4.3)	154 (95.7)		0.6887*			
Male	39	2 (5.1)	37 (94.9)					
Age at AR diagnosis:								
≤ 45	102	4 (3.9)	98 (96.1)		0.744*			
> 45	98	5 (5.1)	93 (94.9)					
Duration of methotrexate treatment:								
≤ 46	102	5 (4.9)	97 (95.1)		1*			
> 46	98	4 (4.1)	94 (95.9)					
Smoking status:								
Current-smokers	45	2 (4.4)	43 (95.6)		1*			
Former-smokers	12	0 (0.0)	12 (100.0)					
Non-smokers	143	7 (4.9)	136 (95.1)					
Baseline FR status:								
Positive	136	6 (4.4)	130 (95.6)		1*			
Negative	63	2 (3.2)	61 (96.8)					
Baseline DAS28 status:								
≤ 5.42	98	4 (4.1)	94 (95.9)		1*			
> 5.42	101	4 (4.0)	97 (96.0)					

*P-value for Fisher's Exact Test.

Supplementary Table SXVII. Hardy-Weinberg equilibrium

Chr	SNP	Minor allele	Major allele	Genotype counts	Observed heterozygosity	Expected heterozygosity	P-value
1	rs1801133	T	C	46/94/60	0.47	0.4975	0.4771
1	rs1801131	C	A	16/63/120	0.3166	0.3634	0.07816
1	rs1805087	C	T	3/60/137	0.3	0.2756	0.3045
7	rs1045642	T	C	42/93/65	0.465	0.4934	0.4732
9	rs4986790	C	T	3/24/173	0.12	0.1388	0.08288
10	rs4148396	T	C	44/96/60	0.48	0.4968	0.6696
14	rs2236225	T	C	38/99/63	0.495	0.4922	1

Chr – chromosome.

Supplementary Table SXVIII. Linkage disequilibrium

Chr	BP	SNP	Chr	BP	SNP	R2	D
1	11796321	rs1801133	1	11794419	rs1801131	0.247765	0.938

Chr – chromosome, *BP* – physical position (base-pair).

Supplementary Table SXIX. Clinical characteristics and correlation with macrocytosis

Gene	SNPs	Genotype	N	Macrocytosis		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	1 (1.5)	64 (98.5)	0.5120*				
		CT	93	4 (4.3)	89 (95.7)					
		TT	42	0 (0.0)	42 (100.0)					
		C	158	5 (3.2)	153 (96.8)	0.5860*				
		T	135	4 (3.0)	131 (97.0)	1*				
ABCC2	rs4148396	CC	60	5 (8.3)	55 (91.7)	0.0026*				
		CT	96	0 (0.0)	96 (100.0)					
		TT	44	0 (0.0)	44 (100.0)					
		C	156	5 (3.2)	151 (96.8)	0.5881*				
		T	140	0 (0.0)	140 (100.0)	0.0022*	T	Inf	Inf-Inf	
MTHFD1	rs2236225	CC	63	2 (3.2)	61 (96.8)	0.8519*				
		CT	99	2 (2.0)	97 (98.0)					
		TT	38	1 (2.6)	37 (97.4)					
		C	162	4 (2.5)	158 (97.5)	1*				
		T	137	3 (2.2)	134 (97.8)	0.6511*				
MTHFR	rs1801131	AA	120	2 (1.7)	118 (98.3)	0.5688*				
		AC	63	3 (4.8)	60 (95.2)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	5 (2.7)	178 (97.3)	1*				
		C	79	3 (3.8)	76 (96.2)	0.3875*				
	rs1801133	CC	60	2 (3.3)	58 (96.7)	0.8541*				
		CT	94	2 (2.1)	92 (97.9)					
		TT	46	1 (2.2)	45 (97.8)					
		C	154	4 (2.6)	150 (97.4)	1*				
		T	140	3 (2.1)	137 (97.9)	0.6373*				
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	60	1 (1.7)	59 (98.3)					
		TT	137	4 (2.9)	133 (97.1)					
		C	63	1 (1.6)	62 (98.4)	1*				
		T	197	5 (2.5)	192 (97.5)	1*				
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	0.1784*				
		CT	24	2 (8.3)	22 (91.7)					
		TT	173	3 (1.7)	170 (98.3)					
		C	27	2 (7.4)	25 (92.6)	0.1358*				
		T	197	5 (2.5)	192 (97.5)	1*				

*P-value for Fisher's Exact Test. Inf – Infinite.

Supplementary Table SXX. Polymorphisms and correlation with anaemia

Gene	SNPs	Genotype	N	Anaemia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	3 (4.6)	62 (95.4)	0.3981*				
		CT	93	8 (8.6)	85 (91.4)					
		TT	42	1 (2.4)	41 (97.6)					
		C	158	11 (7.0)	147 (93.0)	0.4663*				
		T	135	9 (6.7)	126 (93.3)	0.7545*				
ABCC2	rs4148396	CC	60	3 (5.0)	57 (95.0)	0.6817*				
		CT	96	5 (5.2)	91 (94.8)					
		TT	44	4 (9.1)	40 (90.9)					
		C	156	8 (5.1)	148 (94.9)	0.3026*				
		T	140	9 (6.4)	131 (93.6)	1*				
MTHFD1	rs2236225	CC	63	6 (9.5)	57 (90.5)	0.1444*				
		CT	99	6 (6.1)	93 (93.9)					
		TT	38	0 (0.0)	38 (100.0)					
		C	162	12 (7.4)	150 (92.6)	0.1278*				
		T	137	6 (4.4)	131 (95.6)	0.1997*				
MTHFR	rs1801131	AA	120	10 (8.3)	110 (91.7)	0.3094*				
		AC	63	2 (3.2)	61 (96.8)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	12 (6.6)	171 (93.4)	0.6039*				
		C	79	2 (2.5)	77 (97.5)	0.1295*				
	rs1801133	CC	60	1 (1.7)	59 (98.3)	0.0523*				
		CT	94	5 (5.3)	89 (94.7)					
		TT	46	6 (13.0)	40 (87.0)					
		C	154	6 (3.9)	148 (96.1)					
T	140	11 (7.9)	129 (92.1)	0.1125*						
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	60	3 (5.0)	57 (95.0)					
		TT	137	9 (6.6)	128 (93.4)					
		C	63	3 (4.8)	60 (95.2)	0.7563*				
		T	197	12 (6.1)	185 (93.9)	1*				
TLR4	rs4986790	CC	3	1 (33.3)	2 (66.7)	0.1043*				
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	11 (6.4)	162 (93.6)					
		C	27	1 (3.7)	26 (96.3)	1*				
		T	197	11 (5.6)	186 (94.4)	0.1702*				

*P-value for Fisher's Exact Test.

Supplementary Table SXXI. Polymorphisms and correlation with neutropaenia

Gene	SNPs	Genotype	N	Neutropaenia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	4 (6.2)	61 (93.8)	0.2788*				
		CT	93	10 (10.8)	83 (89.2)					
		TT	42	1 (2.4)	41 (97.6)					
		C	158	14 (8.9)	144 (91.1)	0.2021*				
		T	135	11 (8.1)	124 (91.9)	0.7777*				
ABCC2	rs4148396	CC	60	4 (6.7)	56 (93.3)	0.8825*				
		CT	96	7 (7.3)	89 (92.7)					
		TT	44	4 (9.1)	40 (90.9)					
		C	156	11 (7.1)	145 (92.9)	0.7456*				
		T	140	11 (7.9)	129 (92.1)	1*				
MTHFD1	rs2236225	CC	63	6 (9.5)	57 (90.5)	0.4909*				
		CT	99	8 (8.1)	91 (91.9)					
		TT	38	1 (2.6)	37 (97.4)					
		C	162	14 (8.6)	148 (91.4)	0.3116*				
		T	137	9 (6.6)	128 (93.4)	0.5641*				
MTHFR	rs1801131	AA	120	11 (9.2)	109 (90.8)	0.6483*				
		AC	63	3 (4.8)	60 (95.2)					
		CC	16	1 (6.2)	15 (93.8)					
		A	183	14 (7.7)	169 (92.3)	1*				
		C	79	4 (5.1)	75 (94.9)	0.6374	0.4246			
	rs1801133	CC	60	2 (3.3)	58 (96.7)	0.1664*				
		CT	94	7 (7.4)	87 (92.6)					
		TT	46	6 (13.0)	40 (87.0)					
		C	154	9 (5.8)	145 (94.2)	0.1162*				
		T	140	13 (9.3)	127 (90.7)	0.2395*				
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	0.6524*				
		CT	60	3 (5.0)	57 (95.0)					
		TT	137	12 (8.8)	125 (91.2)					
		C	63	3 (4.8)	60 (95.2)	0.3978*				
		T	197	15 (7.6)	182 (92.4)	1*				
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	0.7627*				
		CT	24	1 (4.2)	23 (95.8)					
		TT	173	14 (8.1)	159 (91.9)					
		C	27	1 (3.7)	26 (96.3)	0.6982*				
		T	197	15 (7.6)	182 (92.4)	1*				

*P-value for Fisher's Exact Test.

Supplementary Table SXXII. Polymorphisms and correlation with thrombocytopenia

Gene	SNPs	Genotype	N	Thrombocytopenia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	0 (0.0)	65 (100.0)	0.3109*	1*			
		CT	93	3 (3.2)	90 (96.8)					
		TT	42	0 (0.0)	42 (100.0)					
		C	158	3 (1.9)	155 (98.1)					
		T	135	3 (2.2)	132 (97.8)					
ABCC2	rs4148396	CC	60	0 (0.0)	60 (100.0)	0.5987*	1*			
		CT	96	2 (2.1)	94 (97.9)					
		TT	44	1 (2.3)	43 (97.7)					
		C	156	2 (1.3)	154 (98.7)					
		T	140	3 (2.1)	137 (97.9)					
MTHFD1	rs2236225	CC	63	2 (3.2)	61 (96.8)	0.5869*	1*			
		CT	99	1 (1.0)	98 (99.0)					
		TT	38	0 (0.0)	38 (100.0)					
		C	162	3 (1.9)	159 (98.1)					
		T	137	1 (0.7)	136 (99.3)					
MTHFR	rs1801131	AA	120	3 (2.5)	117 (97.5)	0.6523*	1*			
		AC	63	0 (0.0)	63 (100.0)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	3 (1.6)	180 (98.4)					
		C	79	0 (0.0)	79 (100.0)					
	rs1801133	CC	60	1 (1.7)	59 (98.3)	0.8003*	1*			
		CT	94	1 (1.1)	93 (98.9)					
		TT	46	1 (2.2)	45 (97.8)					
		C	154	2 (1.3)	152 (98.7)					
		T	140	2 (1.4)	138 (98.6)					
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	0.5744*	1*			
		CT	60	0 (0.0)	60 (100.0)					
		TT	137	3 (2.2)	134 (97.8)					
		C	63	0 (0.0)	63 (100.0)					
		T	197	3 (1.5)	194 (98.5)					
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	1*	1*			
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	3 (1.7)	170 (98.3)					
		C	27	0 (0.0)	27 (100.0)					
		T	197	3 (1.5)	194 (98.5)					

*P-value for Fisher's Exact Test.

Supplementary Table SXXIII. Polymorphisms and correlation with dizziness

Gene	SNPs	Genotype	N	Dizziness		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	8 (12.3)	57 (87.7)	1.8074	0.4051			
		CT	93	8 (8.6)	85 (91.4)					
		TT	42	2 (4.8)	40 (95.2)					
		C	158	16 (10.1)	142 (89.9)		0.3739*			
		T	135	10 (7.4)	125 (92.6)	0.7577	0.3841			
ABCC2	rs4148396	CC	60	4 (6.7)	56 (93.3)		0.5858			
		CT	96	11 (11.5)	85 (88.5)					
		TT	44	3 (6.8)	41 (93.2)					
		C	156	15 (9.6)	141 (90.4)		0.7681*			
		T	140	14 (10.0)	126 (90.0)	0.2355	0.6275			
MTHFD1	rs2236225	CC	63	6 (9.5)	57 (90.5)	0.0788	0.9614			
		CT	99	9 (9.1)	90 (90.9)					
		TT	38	3 (7.9)	35 (92.1)					
		C	162	15 (9.3)	147 (90.7)		1*			
		T	137	12 (8.8)	125 (91.2)	< 0.01	1*			
MTHFR	rs1801131	AA	120	13 (10.8)	107 (89.2)	2.6884	0.2608			
		AC	63	4 (6.3)	59 (93.7)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	17 (9.3)	166 (90.7)		0.3697*			
		C	79	4 (5.1)	75 (94.9)	1.3587	0.2438			
	rs1801133	CC	60	1 (1.7)	59 (98.3)	5.6961	0.0579			
		CT	94	11 (11.7)	83 (88.3)					
		TT	46	6 (13.0)	40 (87.0)					
		C	154	12 (7.8)	142 (92.2)		0.3763*			
		T	140	17 (12.1)	123 (87.9)	4.4218	0.0355	CC	8.15	1.06–62.75
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)		0.8432*			
		CT	60	6 (10.0)	54 (90.0)					
		TT	137	12 (8.8)	125 (91.2)					
		C	63	6 (9.5)	57 (90.5)	< 0.01	1*			
		T	197	18 (9.1)	179 (90.9)		1*			
TLR4	rs4986790	CC	3	1 (33.3)	2 (66.7)		0.3499*			
		CT	24	2 (8.3)	22 (91.7)					
		TT	173	15 (8.7)	158 (91.3)					
		C	27	3 (11.1)	24 (88.9)		0.7163*			
		T	197	17 (8.6)	180 (91.4)		0.2476*			

*P-value for Fisher's Exact Test.

Supplementary Table SXXIV. Polymorphisms and correlation with headache

Gene	SNPs	Genotype	N	Headache		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	9 (13.8)	56 (86.2)	2.5388	0.2810			
		CT	93	6 (6.5)	87 (93.5)					
		TT	42	5 (11.9)	37 (88.1)					
		C	158	15 (9.5)	143 (90.5)	0.5767*				
		T	135	11 (8.1)	124 (91.9)	1.0130	0.3142			
ABCC2	rs4148396	CC	60	3 (5.0)	57 (95.0)	4.9811	0.0829			
		CT	96	9 (9.4)	87 (90.6)					
		TT	44	8 (18.2)	36 (81.8)					
		C	156	12 (7.7)	144 (92.3)	0.04965*	C	2.67	1.01–7.01	
		T	140	17 (12.1)	123 (87.9)	1.6534	0.1985			
MTHFD1	rs2236225	CC	63	9 (14.3)	54 (85.7)	2.2413	0.3261			
		CT	99	7 (7.1)	92 (92.9)					
		TT	38	4 (10.5)	34 (89.5)					
		C	162	16 (9.9)	146 (90.1)	1*				
		T	137	11 (8.0)	126 (92.0)	1.2462	0.2643			
MTHFR	rs1801131	AA	120	13 (10.8)	107 (89.2)	3.4694	0.1765			
		AC	63	3 (4.8)	60 (95.2)					
		CC	16	3 (18.8)	13 (81.2)					
		A	183	16 (8.7)	167 (91.3)	0.1852*				
		C	79	6 (7.6)	73 (92.4)	0.2642	0.6072			
	rs1801133	CC	60	5 (8.3)	55 (91.7)	0.2663	0.8753			
		CT	94	10 (10.6)	84 (89.4)					
		TT	46	5 (10.9)	41 (89.1)					
		C	154	15 (9.7)	139 (90.3)	0.7841*				
		T	140	15 (10.7)	125 (89.3)	0.0661	0.7970			
MTR	rs1805087	CC	3	0 (0.0)	3 (2.7)		0.2699*			
		CT	60	3 (6.0)	57 (54.0)					
		TT	137	17 (13.7)	120 (123.3)					
		C	63	3 (4.8)	60 (95.2)	2.0186	0.1554			
		T	197	20 (10.2)	177 (89.8)	1*				
TLR4	rs4986790	CC	3	1 (33.3)	2 (66.7)		0.3745*			
		CT	24	2 (8.3)	22 (91.7)					
		TT	173	7 (9.8)	156 (90.2)					
		C	27	3 (11.1)	24 (88.9)	0.0428	0.8361			
		T	197	19 (9.6)	178 (90.4)	0.2722*				

*P-value for Fisher's Exact Test.

Supplementary Table SXXV. Polymorphisms and correlation with mucositis

Gene	SNPs	Genotype	N	Mucositis		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	10 (15.4)	55 (84.6)	3.7048	0.1569			
		CT	93	6 (6.5)	87 (93.5)					
		TT	42	6 (14.3)	36 (85.7)					
		C	158	16 (10.1)	142 (89.9)		0.417*			
		T	135	12 (8.9)	123 (91.1)	1.2857	0.2568			
ABCC2	rs4148396	CC	60	4 (6.7)	56 (93.3)	1.7902	0.4086			
		CT	96	13 (13.5)	83 (86.5)					
		TT	44	5 (11.4)	39 (88.6)					
		C	156	17 (10.9)	139 (89.1)		1*			
		T	140	18 (12.9)	122 (87.1)	1.0725	0.3004			
MTHFD1	rs2236225	CC	63	5 (7.9)	58 (92.1)	3.6243	0.1633			
		CT	99	15 (15.2)	84 (84.8)					
		TT	38	2 (5.3)	36 (94.7)					
		C	162	20 (12.3)	142 (87.7)		0.2621*			
		T	137	17 (12.4)	120 (87.6)	0.4840	0.4866			
MTHFR	rs1801131	AA	120	8 (6.7)	112 (93.3)	8.6058	0.0135			
		AC	63	13 (20.6)	50 (79.4)					
		CC	16	1 (6.2)	15 (93.8)					
		A	183	21 (11.5)	162 (88.5)		1*			
		C	79	14 (17.7)	65 (82.3)	4.8498	0.02765	AA	3.02	1.20–7.57
	rs1801133	CC	60	9 (15.0)	51 (85.0)	3.1072	0.2115			
		CT	94	11 (11.7)	83 (88.3)					
		TT	46	2 (4.3)	44 (95.7)					
		C	154	20 (13.0)	134 (87.0)	1.8899	0.1692			
		T	140	13 (9.3)	127 (90.7)	0.8779	0.3488			
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)		0.4550*			
		CT	60	4 (6.7)	56 (93.3)					
		TT	137	18 (13.1)	119 (86.9)					
		C	63	4 (6.3)	59 (93.7)	1.3977	0.2371			
		T	197	22 (11.2)	175 (88.8)		1*			
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)		0.8145*			
		CT	24	3 (12.5)	21 (87.5)					
		TT	173	19 (11.0)	154 (89.0)					
		C	27	3 (11.1)	24 (88.9)		1*			
		T	197	22 (11.2)	175 (88.8)		1*			

*P-value for Fisher's Exact Test.

Supplementary Table SXXVI. Clinical characteristics and correlation with acneiform rash

Gene	SNPs	Genotype	N	Rash acneiform		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	2 (3.1)	63 (96.9)	0.6113*				
		CT	93	4 (4.3)	89 (95.7)					
		TT	42	3 (7.1)	39 (92.9)					
		C	158	6 (3.8)	152 (96.2)					
		T	135	7 (5.2)	128 (94.8)					
ABCC2	rs4148396	CC	60	1 (1.7)	59 (98.3)	0.3989*				
		CT	96	5 (5.2)	91 (94.8)					
		TT	44	3 (6.8)	41 (93.2)					
		C	156	6 (3.8)	150 (96.2)					
		T	140	8 (5.7)	132 (94.3)					
MTHFD1	rs2236225	CC	63	2 (3.2)	61 (96.8)	0.5361*				
		CT	99	4 (4.0)	95 (96.0)					
		TT	38	3 (7.9)	35 (92.1)					
		C	162	6 (3.7)	156 (96.3)					
		T	137	7 (5.1)	130 (94.9)					
MTHFR	rs1801131	AA	120	2 (1.7)	118 (98.3)	0.0131*				
		AC	63	7 (11.1)	56 (88.9)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	9 (4.9)	174 (95.1)					
		C	79	7 (8.9)	72 (91.1)					
	rs1801133	CC	60	4 (6.7)	56 (93.3)	0.2002				
		CT	94	5 (5.3)	89 (94.7)					
		TT	46	0 (0.0)	46 (100.0)					
		C	154	9 (5.8)	145 (94.2)					
		T	140	5 (3.6)	135 (96.4)					
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	60	3 (5.0)	57 (95.0)					
		TT	137	6 (4.4)	131 (95.6)					
		C	63	3 (4.8)	60 (95.2)					
		T	197	9 (4.6)	188 (95.4)					
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	0.2008*				
		CT	24	3 (12.5)	21 (87.5)					
		TT	173	6 (3.5)	167 (96.5)					
		C	27	3 (11.1)	24 (88.9)					
		T	197	9 (4.6)	188 (95.4)					

*P-value for Fisher's Exact Test.

Supplementary Table SXXVII. Polymorphisms and correlation with anosmia

Gene	SNPs	Genotype	N	Anosmia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	0 (0.0)	65 (100.0)	0.4813*				
		CT	93	1 (1.1)	92 (98.9)					
		TT	42	1 (2.4)	41 (97.6)					
		C	158	1 (0.6)	157 (99.4)	0.3767*				
		T	135	2 (1.5)	133 (98.5)	1*				
ABCC2	rs4148396	CC	60	2 (3.3)	58 (96.7)	0.1365*				
		CT	96	0 (0.0)	96 (100.0)					
		TT	44	0 (0.0)	44 (100.0)					
		C	156	2 (1.3)	154 (98.7)	1*				
		T	140	0 (0.0)	140 (100.0)	0.0889				
MTHFD1	rs2236225	CC	63	1 (1.6)	62 (98.4)	0.2538*				
		CT	99	0 (0.0)	99 (100.0)					
		TT	38	1 (2.6)	37 (97.4)					
		C	162	1 (0.6)	161 (99.4)	0.3447*				
		T	137	1 (0.7)	136 (99.3)	0.5319*				
MTHFR	rs1801131	AA	120	0 (0.0)	120 (100.0)	0.2538*				
		AC	63	2 (3.2)	61 (96.8)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	2 (1.1)	181 (98.9)	1*				
		C	79	2 (2.5)	77 (97.5)	0.1564*				
	rs1801133	CC	60	0 (0.0)	60 (100.0)	0.4969*				
		CT	94	1 (1.1)	93 (98.9)					
		TT	46	1 (2.2)	45 (97.8)					
		C	154	1 (0.6)	153 (99.4)	0.4080*				
		T	140	2 (1.4)	138 (98.6)	1*				
MTR	rs1805087	CC	3	1 (33.3)	2 (66.7)	0.0092*				
		CT	60	1 (1.7)	59 (98.3)					
		TT	137	0 (0.0)	137 (100.0)					
		C	63	2 (3.2)	61 (96.8)	0.0981*				
		T	197	1 (0.5)	196 (99.5)	0.0298*	T	98.00	4.41– 2180.05	
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	2 (1.2)	171 (98.8)					
		C	27	0 (0.0)	27 (100.0)	1*				
		T	197	2 (1.0)	195 (99.0)	1*				

*P-value for Fisher's Exact Test. Inf – Infinite.

Supplementary Table SXXVIII. Clinical characteristics and correlation with alopecia

Gene	SNPs	Genotype	N	Alopecia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	5 (7.7)	60 (92.3)	2.507	0.2855			
		CT	93	15 (16.1)	78 (83.9)					
		TT	42	5 (11.9)	37 (88.1)					
		C	158	20 (12.7)	138 (87.3)	0.0172	0.8956			
		T	135	20 (14.8)	115 (85.2)	2.0350	0.1537			
ABCC2	rs4148396	CC	60	10 (16.7)	50 (83.3)	1.3853	0.5003			
		CT	96	10 (10.4)	86 (89.6)					
		TT	44	5 (11.4)	39 (88.6)					
		C	156	20 (12.8)	136 (87.2)	0.0666	0.7964			
		T	140	15 (10.7)	125 (89.3)	1.3605	0.2434			
MTHFD1	rs2236225	CC	60	3 (4.8)	60 (95.2)	5.3034	0.07053			
		CT	84	15 (15.2)	84 (84.8)					
		TT	31	7 (18.4)	31 (81.6)					
		C	162	18 (11.1)	144 (88.9)		0.2731*			
		T	137	22 (16.1)	115 (83.9)	5.0350	0.0248	CC	3.83	1.10–13.30
MTHFR	rs1801131	AA	120	9 (7.5)	111 (92.5)	12.4870	0.0019			
		AC	63	10 (15.9)	53 (84.1)					
		CC	16	6 (7.5)	10 (92.5)					
		A	183	19 (10.4)	164 (89.6)		0.0072*	A	5.11	1.37–17.70
		C	79	16 (20.3)	63 (79.7)	7.0536	0.0079	AA	3.11	1.21–8.49
	rs1801133	CC	60	10 (16.7)	50 (83.3)	1.6158	0.4458			
		CT	94	11 (11.7)	83 (88.3)					
		TT	46	4 (8.7)	42 (91.3)					
		C	154	21 (13.6)	133 (86.4)	0.7905	0.3739			
		T	140	15 (10.7)	125 (89.3)	1.3605	0.2434			
MTR	rs1805087	CC	3	1 (33.3)	2 (66.7)		0.2144*			
		CT	60	5 (8.3)	55 (91.7)					
		TT	137	19 (13.9)	118 (86.1)					
		C	63	6 (9.5)	57 (90.5)	0.74482	0.3881			
		T	197	24 (12.2)	173 (87.8)		0.3315*			
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)		0.6769*			
		CT	24	4 (16.7)	20 (83.3)					
		TT	173	21 (12.1)	152 (87.9)					
		C	27	4 (14.8)	23 (85.2)		0.7537*			
		T	197	25 (12.7)	172 (87.3)		1*			

*P-value for Fisher's Exact Test. Inf – Infinite.

Supplementary Table SXXIX. Polymorphisms and correlation with liver failure

Gene	SNPs	Genotype	N	Liver failure		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	61	24 (39.3)	37 (60.7)	1.8376	0.3990			
		CT	92	45 (48.9)	47 (51.1)					
		TT	41	21 (51.2)	20 (48.8)					
		C	153	69 (45.1)	84 (54.9)	0.2722	0.6019			
		T	133	66 (49.6)	67 (50.4)	1.3876	0.2388			
ABCC2	rs4148396	CC	59	27 (45.8)	32 (54.2)	0.1944	0.9074			
		CT	94	45 (47.9)	49 (52.1)					
		TT	41	18 (43.9)	23 (56.1)					
		C	153	72 (47.1)	81 (52.9)	0.1295	0.7189			
		T	135	63 (46.7)	72 (53.3)	0.0135	0.9075			
MTHFD1	rs2236225	CC	60	24 (40.0)	36 (60.0)	5.5502	0.0623			
		CT	96	42 (43.8)	54 (56.2)					
		TT	38	24 (63.2)	14 (36.8)					
		C	156	66 (42.3)	90 (57.7)	4.5359	0.0332	C	2.34	1.12–4.86
		T	134	66 (49.3)	68 (50.7)	1.0791	0.2989			
MTHFR	rs1801131	AA	119	57 (47.9)	62 (52.1)					
		AC	59	23 (39.0)	36 (61.0)					
		CC	15	10 (66.7)	5 (33.3)					
		A	178	80 (44.9)	98 (55.1)	1.8229	0.1770			
		C	74	33 (44.6)	41 (55.4)	0.0894	0.7649			
	rs1801133	CC	59	30 (50.8)	29 (49.2)	0.8109	0.6667			
		CT	90	41 (45.6)	49 (54.4)					
		TT	45	19 (42.2)	26 (57.8)					
		C	149	71 (47.7)	78 (52.3)	0.2204	0.6388			
		T	135	60 (44.4)	75 (55.6)	0.4439	0.5053			
MTR	rs1805087	CC	3	3 (100.0)	0 (0.0)		0.1438*			
		CT	57	28 (49.1)	29 (50.9)					
		TT	134	59 (44.0)	75 (56.0)					
		C	60	31 (51.7)	29 (48.3)	0.3526*				
		T	191	87 (45.5)	104 (54.5)	0.0981*				
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)		0.3094*			
		CT	23	12 (52.2)	11 (47.8)					
		TT	168	78 (46.4)	90 (53.6)					
		C	26	12 (46.2)	14 (53.8)	0.0007	0.9791			
		T	191	90 (47.1)	101 (52.9)	0.2500*				

*P-value for Fisher's Exact Test.

Supplementary Table SXXX. Polymorphisms and correlation with diarrhoea

Gene	SNPs	Genotype	N	Diarrhoea		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	8 (12.3)	57 (87.7)	1.5300	0.4653			
		CT	93	18 (19.4)	75 (80.6)					
		TT	42	6 (14.3)	36 (85.7)					
		C	158	26 (16.5)	132 (83.5)	0.0109	0.9170			
		T	135	24 (17.8)	111 (82.2)	0.6122	0.4340			
ABCC2	rs4148396	CC	60	9 (15.0)	51 (85.0)	0.2105	0.9001			
		CT	96	15 (15.6)	81 (84.4)					
		TT	44	8 (18.2)	36 (81.8)					
		C	156	24 (15.4)	132 (84.6)	0.0459	0.8304			
		T	140	23 (16.4)	117 (83.6)	0.0018	0.9664			
MTHFD1	rs2236225	CC	63	11 (17.5)	52 (82.5)	2.3081	0.3154			
		CT	99	18 (18.2)	81 (81.8)					
		TT	38	3 (7.9)	35 (92.1)					
		C	162	29 (17.9)	133 (82.1)	1.6091	0.2046			
		T	137	21 (15.3)	116 (84.7)	0.0304	0.8616			
MTHFR	rs1801131	AA	120	19 (15.8)	101 (84.2)	1.5622	0.4579			
		AC	63	12 (19.0)	51 (81.0)					
		CC	16	1 (6.2)	15 (93.8)					
		A	183	31 (16.9)	152 (83.1)	0.4769*				
		C	79	13 (16.5)	66 (83.5)	< 0.01	1			
	rs1801133	CC	60	8 (13.3)	52 (86.7)	0.4567	0.7959			
		CT	94	16 (17.0)	78 (83.0)					
		TT	46	8 (17.4)	38 (82.6)					
		C	154	24 (15.6)	130 (84.4)	0.0041	0.9488			
		T	140	24 (17.1)	116 (82.9)	0.2144	0.6434			
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)		0.8081*			
		CT	60	11 (18.3)	49 (81.7)					
		TT	137	21 (15.3)	116 (84.7)					
		C	63	11 (17.5)	52 (82.5)	0.0304	0.8616			
		T	197	32 (16.2)	165 (83.8)		1*			
TLR4	rs4986790	CC	3	1 (33.3)	2 (66.7)		0.4719*			
		CT	24	3 (12.5)	21 (87.5)					
		TT	173	28 (16.2)	145 (83.8)					
		C	27	4 (14.8)	23 (85.2)		1*			
		T	197	31 (15.7)	166 (84.3)		0.4090*			

*P-value for Fisher's Exact Test.

Supplementary Table SXXXI. Polymorphisms and correlation with nausea and vomiting

Gene	SNPs	Genotype	N	Nausea and vomiting		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	16 (24.6)	49 (75.4)	0.6839	0.7104			
		CT	93	19 (20.4)	74 (79.6)					
		TT	42	11 (26.2)	31 (73.8)					
		C	158	35 (22.2)	123 (77.8)	0.1201	0.7289			
		T	135	30 (22.2)	105 (77.8)	0.0389	0.8436			
ABCC2	rs4148396	CC	60	11 (18.3)	49 (81.7)	1.0540	0.5904			
		CT	96	24 (25.0)	72 (75.0)					
		TT	44	11 (25.0)	33 (75.0)					
		C	156	35 (22.4)	121 (77.6)	0.0238	0.8775			
		T	140	35 (25.0)	105 (75.0)	0.7112	0.3990			
MTHFD1	rs2236225	CC	63	12 (19.0)	51 (81.0)	1.2321	0.5401			
		CT	99	26 (26.3)	73 (73.7)					
		TT	38	8 (21.1)	30 (78.9)					
		C	162	38 (23.5)	124 (76.5)	0.0106	0.9181			
		T	137	34 (24.8)	103 (75.2)	0.5182	0.4716			
MTHFR	rs1801131	AA	120	30 (25.0)	90 (75.0)	1.4667	0.4803			
		AC	63	13 (20.6)	50 (79.4)					
		CC	16	2 (12.5)	14 (87.5)					
		A	183	43 (23.5)	140 (76.5)	0.5325*				
		C	79	15 (19.0)	64 (81.0)	0.6706	0.4129			
	rs1801133	CC	60	13 (21.7)	47 (78.3)	0.9368	0.6260			
		CT	94	20 (21.3)	74 (78.7)					
		TT	46	13 (28.3)	33 (71.7)					
		C	154	33 (21.4)	121 (78.6)	0.5877	0.4433			
		T	140	33 (23.6)	197 (76.4)	0.0121	0.9124			
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)		1*			
		CT	60	14 (23.3)	46 (76.7)					
		TT	137	32 (23.4)	105 (76.6)					
		C	63	14 (22.2)	49 (77.8)	< 0.01	1			
		T	197	46 (23.4)	151 (76.6)		1*			
TLR4	rs4986790	CC	3	2 (66.7)	1 (33.3)		0.1869*			
		CT	24	4 (16.7)	20 (83.3)					
		TT	173	40 (23.1)	133 (76.9)					
		C	27	6 (22.2)	21 (77.8)	< 0.01	1			
		T	197	44 (22.3)	153 (77.7)		0.1329*			

*P-value for Fisher's Exact Test.

Supplementary Table SXXXII. Clinical characteristics and correlation with anxiety

Gene	SNPs	Genotype	N	Anxiety		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	0 (0.0)	65 (100.0)	0.2100*	0.2100*			
		CT	93	0 (0.0)	93 (100.0)					
		TT	42	1 (2.4)	41 (97.6)					
		C	158	0 (0.0)	158 (100.0)					
		T	135	1 (0.7)	134 (99.3)					
ABCC2	rs4148396	CC	60	1 (1.7)	59 (98.3)	0.5200*	0.5200*			
		CT	96	0 (0.0)	96 (100.0)					
		TT	44	0 (0.0)	44 (100.0)					
		C	156	1 (0.6)	155 (99.4)					
		T	140	0 (0.0)	140 (100.0)					
MTHFD1	rs2236225	CC	63	0 (0.0)	63 (100.0)	1*	1*			
		CT	99	1 (1.0)	98 (99.0)					
		TT	38	0 (0.0)	38 (100.0)					
		C	162	1 (0.6)	161 (99.4)					
		T	137	1 (0.7)	136 (99.3)					
MTHFR	rs1801131	AA	120	0 (0.0)	120 (100.0)	0.0804*	0.0804*			
		AC	63	0 (0.0)	63 (100.0)					
		CC	16	1 (6.2)	15 (93.8)					
		A	183	0 (0.0)	183 (100.0)					
		C	79	1 (1.3)	78 (98.7)					
	rs1801133	CC	60	1 (1.7)	59 (98.3)	0.5300*	0.5300*			
		CT	94	0 (0.0)	94 (100.0)					
		TT	46	0 (0.0)	46 (100.0)					
		C	154	1 (0.6)	153 (99.4)					
		T	140	0 (0.0)	140 (100.0)					
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	1*	1*			
		CT	60	0 (0.0)	60 (100.0)					
		TT	137	1 (0.7)	136 (99.3)					
		C	63	0 (0.0)	63 (100.0)					
		T	197	1 (0.5)	196 (99.5)					
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	1*	1*			
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	1 (0.6)	172 (99.4)					
		C	27	0 (0.0)	27 (100.0)					
		T	197	1 (0.5)	196 (99.5)					

*P-value for Fisher's Exact Test. Inf – Infinite.

Supplementary Table SXXXIII. Clinical characteristics and correlation with metrorrhagia

Gene	SNPs	Genotype	N	Metrorrhagia		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	1 (1.5)	64 (98.5)	0.7883*				
		CT	93	1 (1.1)	92 (98.9)					
		TT	42	1 (2.4)	41 (97.6)					
		C	158	2 (1.3)	156 (98.7)	0.5089*				
		T	135	2 (1.5)	133 (98.5)	1*				
ABCC2	rs4148396	CC	60	0 (0.0)	60 (100.0)	0.3166*				
		CT	96	3 (3.1)	93 (96.9)					
		TT	44	0 (0.0)	44 (100.0)					
		C	156	3 (1.9)	153 (98.1)	1*				
		T	140	3 (2.1)	137 (97.9)	0.5555*				
MTHFD1	rs2236225	CC	63	2 (3.2)	61 (96.8)	0.5869*				
		CT	99	1 (1.0)	98 (99.0)					
		TT	38	0 (0.0)	38 (100.0)					
		C	162	3 (1.9)	159 (98.1)	1*				
		T	137	1 (0.7)	136 (99.3)	0.2340*				
MTHFR	rs1801131	AA	120	2 (1.7)	118 (98.3)	1*				
		AC	63	1 (1.6)	62 (98.4)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	3 (1.6)	180 (98.4)	1*				
		C	79	1 (1.3)	78 (98.7)	1*				
	rs1801133	CC	60	1 (1.7)	59 (98.3)	0.8003*				
		CT	94	1 (1.1)	93 (98.9)					
		TT	46	1 (2.2)	45 (97.8)					
		C	154	2 (1.3)	152 (98.7)	0.5455*				
		T	140	2 (1.4)	138 (98.6)	1*				
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	60	1 (1.7)	59 (98.3)					
		TT	137	2 (1.5)	135 (98.5)					
		C	63	1 (1.6)	62 (98.4)	1*				
		T	197	3 (1.5)	194 (98.5)	1*				
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	1*				
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	3 (1.7)	170 (98.3)					
		C	27	0 (0.0)	27 (100.0)	1*				
		T	197	3 (1.5)	194 (98.5)	1*				

*P-value for Fisher's Exact Test.

Supplementary Table SXXXIV. Polymorphisms and correlation with pulmonary fibrosis

Gene	SNPs	Genotype	N	Pulmonary toxicity		χ^2	P-value	Cat Ref.	OR	95% CI
				Yes n (%)	No n (%)					
ABCB1	rs1045642	CC	65	2 (3.1)	63 (96.9)	0.7841*				
		CT	93	3 (3.2)	90 (96.8)					
		TT	42	2 (4.8)	40 (95.2)					
		C	158	5 (3.2)	153 (96.8)	0.6390*				
		T	135	5 (3.7)	130 (96.3)	1*				
ABCC2	rs4148396	CC	60	3 (5.0)	57 (95.0)	0.4699*				
		CT	96	4 (4.2)	92 (95.8)					
		TT	44	0 (0.0)	44 (100.0)					
		C	156	7 (4.5)	149 (95.5)	0.3512*				
		T	140	4 (2.9)	136 (97.1)	0.4304*				
MTHFD1	rs2236225	CC	63	1 (1.6)	62 (98.4)	0.1854*				
		CT	99	6 (6.1)	93 (93.9)					
		TT	38	0 (0.0)	38 (100.0)					
		C	162	7 (4.3)	155 (95.7)	0.3507*				
		T	137	6 (4.4)	131 (95.6)	0.4364*				
MTHFR	rs1801131	AA	120	6 (5.0)	114 (95.0)	0.5666*				
		AC	63	1 (1.6)	62 (98.4)					
		CC	16	0 (0.0)	16 (100.0)					
		A	183	7 (3.8)	176 (96.2)	1*				
		C	79	1 (1.3)	78 (98.7)	0.2474				
	rs1801133	CC	60	1 (1.7)	59 (98.3)	0.5407*				
		CT	94	5 (5.3)	89 (94.7)					
		TT	46	1 (2.2)	45 (97.8)					
		C	154	6 (3.9)	148 (96.1)	1*				
		T	140	6 (4.3)	134 (95.7)	0.6769*				
MTR	rs1805087	CC	3	0 (0.0)	3 (100.0)	0.7105*				
		CT	60	1 (1.7)	59 (98.3)					
		TT	137	6 (4.4)	131 (95.6)					
		C	63	1 (1.6)	62 (98.4)	0.4364*				
		T	197	7 (3.6)	190 (96.4)	1*				
TLR4	rs4986790	CC	3	0 (0.0)	3 (100.0)	0.6416*				
		CT	24	0 (0.0)	24 (100.0)					
		TT	173	7 (96.0)	166 (96.0)					
		C	27	0 (0.0)	27 (100.0)	0.5968*				
		T	197	7 (3.6)	190 (96.4)	1*				

*P-value for Fisher's Exact Test.